title: Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk.
abstract: Heavy physical exertion, emotional stress, heavy meals, and respiratory infection transiently increase the risk of myocardial infarction, sudden cardiac death, and stroke; however, it remains uncertain how to use this information for disease prevention. We determined whether it was feasible for those with either risk factors for cardiovascular disease (CVD) or known CVD to take targeted medication for the hazard duration of the triggering activity to reduce their risk. After a run-in of 1 month, 20 subjects (12 women and 8 men) aged 68.6 years (range 58 to 83) recorded for 2 months all episodes of physical and emotional stress, heavy meal consumption, and respiratory infection. For each episode, the subjects were instructed to take either aspirin 100 mg and propranolol 10 mg (for physical exertion and emotional stress) or aspirin 100 mg alone (for respiratory infection and heavy meal consumption) and to record their adherence. Adherence with taking the appropriate medication was 86% according to the diary entries, with 15 of 20 subjects (75%) achieving ≥80% adherence. Propranolol taken before exertion reduced the peak heart rate compared with similar exercise during the run-in period (118 ± 21 vs 132 ± 16 beats/min, p = 0.016). Most subjects (85%) reported that it was feasible to continue taking the medication in this manner. In conclusion, it is feasible for those with increased CVD risk to identify potential triggers of acute CVD and to take targeted therapy at the time of these triggers.
authors.affiliation: Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia. gtofler@nsccahs.health.nsw.gov.au
authors.forename: Geoffrey H
authors.initials: GH
authors.lastname: Tofler
authors.forename: Monica
authors.initials: M
authors.lastname: Spinaze
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Shaw
authors.forename: Thomas
authors.initials: T
authors.lastname: Buckley
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D005082:Physical Exertion / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D013315:Stress, Psychological / Q000517:prevention & control; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D010975:Platelet Aggregation Inhibitors; D011433:Propranolol; D001241:Aspirin